Compare Eli Lilly And Co (LLY) vs Northrop Grumman Corporation (NOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Northrop Grumman Corporation — how do they compare? Eli Lilly And Co trades at $1,223.27 (market cap $1.08T), while Northrop Grumman Corporation trades at $574.7 (market cap $81.78B). The key difference: Eli Lilly And Co is far larger — about 13.2× Northrop Grumman Corporation's market cap, and Northrop Grumman Corporation pays the higher dividend (1.63%). Which is the better fit depends on your goals.
| LLY | NOC | |
|---|---|---|
Market Cap | $1.08T | $81.78B |
Sector | Health | Industrials |
52-Week High | $1.24K | $768.02 |
52-Week Low | $639.43 | $496.02 |
Enterprise Value | $1.13T | $95.77B |
Dividend Yield | 0.57% | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.
Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.
Northrop Grumman (NOC) trades at $577.89, up 1.1% today, with a bullish technical signal from moving averages and a record $105 billion backlog supporting fundamentals. Recent Q2 2026 earnings beat expectations, with sales growth of 5% and raised full-year guidance (Seeking Alpha, 2026-07-23). Valuation ratios like P/E of 18.3 and ROE of 26.96% reflect strong profitability, though RSI levels indicate overbought conditions.
The outlook is positive due to defense spending tailwinds and strategic contracts, but risks include margin pressure from specific programs and geopolitical volatility. Analysts maintain a buy consensus with a $598.57 price target, suggesting modest upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →
